WO2012133047A1 - Procédé de coloration immunohistologique pour déterminer l'efficacité d'une préparation d'anticorps l'utilisant - Google Patents

Procédé de coloration immunohistologique pour déterminer l'efficacité d'une préparation d'anticorps l'utilisant Download PDF

Info

Publication number
WO2012133047A1
WO2012133047A1 PCT/JP2012/057191 JP2012057191W WO2012133047A1 WO 2012133047 A1 WO2012133047 A1 WO 2012133047A1 JP 2012057191 W JP2012057191 W JP 2012057191W WO 2012133047 A1 WO2012133047 A1 WO 2012133047A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
antigen
tissue
staining
drug
Prior art date
Application number
PCT/JP2012/057191
Other languages
English (en)
Japanese (ja)
Inventor
秀樹 郷田
中野　寧
岡田　尚大
幸祐 権田
元博 武田
憲明 大内
Original Assignee
コニカミノルタエムジー株式会社
国立大学法人東北大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コニカミノルタエムジー株式会社, 国立大学法人東北大学 filed Critical コニカミノルタエムジー株式会社
Priority to JP2013507430A priority Critical patent/JP5900489B2/ja
Publication of WO2012133047A1 publication Critical patent/WO2012133047A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Definitions

  • the present invention relates to a method for determining the effectiveness of an antibody drug using a highly accurate tissue staining method.
  • Cancer is a disease that bisects the cause of death in adults together with vascular diseases such as myocardial infarction and cerebral infarction.
  • vascular diseases such as myocardial infarction and cerebral infarction.
  • the incidence of breast cancer in Japan is lower than in Western countries, but has been increasing in recent years. In 1998, it surpassed the incidence of gastric cancer and became the first female morbidity. According to a recent report by the Ministry of Health, Labor and Welfare in 2005, the annual incidence of breast cancer exceeds 50,000. Similarly, the number is increasing every year in the world, and according to a 2008 WHO report, breast cancer has the highest incidence rate for both men and women, and the annual incidence is over 1.38 million. It accounts for about 23% of women ’s cancer.
  • cancer diagnostics include methods that detect cancer markers that are specifically expressed in specific cancers, cancer markers that leak into blood and tissues, etc. Has been.
  • General screening tests for breast cancer include interviews, palpation, soft x-ray mammography (mammography), ultrasonography, etc. If clinical suspicion arises, cytology and biopsy are performed and pathological diagnosis It is determined whether it is cancer.
  • Pathological diagnosis is important for determining the course of cancer treatment and prognosis, and “HE (hematoxylin and eosin) staining for morphological observation” and “cancer markers” are the core of this diagnosis.
  • Herceptin registered trademark
  • HER2 human epidermal growth factor receptor 2
  • Trastuzumab is known to be a typical anticancer drug for breast cancer.
  • Immunohistochemistry (IHC) method for analyzing the expression of HER2 protein and the like and FISH (Fluorescence in situ hybridization) method for analyzing the amplification of HER2 gene and the like are clinical methods for determining the effectiveness of this drug administration. Widely used in the field.
  • the IHC method is a method of staining and visualizing an anti-HER2 antibody bound to the HER2 antigen site using DAB (Diaminobenzidine), and the expression level of HER2 is detected through the visualized anti-HER2 antibody.
  • DAB Diaminobenzidine
  • the criterion is a rough criterion based only on four stages with a staining level score of 0 to 3, and therefore lacks quantitativeness, and further, the criterion depends on the skill level of the pathologist. It is a clinical problem.
  • the FISH method is a method for amplifying and analyzing the HER2 gene using a probe for detecting the HER2 gene and a probe for detecting the chromosome 17 centromere, and for each chromosome 17 analyzed by the FISH method.
  • the presence or absence of amplification of the HER2 gene can be determined based on the gene copy number of HER2.
  • the FISH method is a quantitative test method, it is not a method for directly evaluating the amount of HER2 protein or the intracellular localization of HER2.
  • the antigenic determinant (epitope) of a therapeutic agent (antibody) targeting HER2 protein is different from that used for detection of HER2 protein in the diagnosis of breast cancer
  • the IHC method using anti-HER2 antibody including the current Hercept test Therefore, it was considered to be inadequate as a method for selecting patients to be treated with trastuzumab. Under such circumstances, it is necessary to develop a method for determining the effectiveness of a medicine containing a highly accurate antibody as a component.
  • the present invention has been made in view of the above problems, and immunohistological staining that enables high-precision staining by using an antibody drug containing an antibody such as trastuzumab as a component as a substance that recognizes a target biological substance. It is an object of the present invention to provide a method for determining the effectiveness of an antibody drug with high accuracy using such an immunohistochemical staining method.
  • the present inventor has found a method capable of selecting a patient suitable for administration of an antibody drug equivalent to confirmation of gene amplification by the FISH method by performing a biological tissue staining method using an antibody drug containing an antibody such as trastuzumab as a component. Invented.
  • the present invention provides an immunohistochemical staining method shown in the following [1] to [7] and a method for determining the effectiveness of an antibody drug.
  • the effectiveness of the antibody drug is determined by measuring the amount of the antibody bound to the amount of the antigen using the immunohistochemical staining method according to any one of [1] to [6]. how to.
  • the immunohistochemical staining method can be carried out with high accuracy, whereby the patient to which the antibody drug is to be administered can be selected more accurately.
  • the labeling substance used in the present invention is not particularly limited as long as it does not interfere with the antigen-antibody reaction and does not interfere with the quantitativeness in the measurement.
  • the antigen-antibody reaction is directly visualized, particularly in a visible form.
  • a labeling substance that can detect the presence of the complex formed by the antigen-antibody reaction by color development is preferably used.
  • directly visualization in a visible form means that the location of the antigen-antibody reaction can be directly observed without secondary operations such as development.
  • Examples of such a labeling substance include a substance that itself can develop color, or an enzyme that can generate a substance that develops color from a suitable substrate.
  • the “chromogenic substance itself” is not particularly limited as long as it is a substance that can easily identify the presence or absence of the complex produced by the antigen-antibody reaction, but it is easy to identify the color development. From the point of view, there are fluorescent labeling agents such as organic fluorescent dyes, quantum dots, and fluorescent aggregates obtained by integrating a plurality of fluorescent substances.
  • Organic fluorescent dyes include fluorescein dye molecules, rhodamine dye molecules, Alexa Fluor (Invitrogen) dye molecules, BODIPY (Invitrogen) dye molecules, cascade dye molecules, coumarin dye molecules, and eosin dyes. Examples include molecules, NBD dye molecules, pyrene dye molecules, Texas Red dye molecules, cyanine dye molecules, perylene dye molecules, and oxazine dye molecules.
  • organic fluorescent dyes may be used alone or in combination of two or more.
  • quantum dots containing II-VI group compounds, III-V group compounds, or IV group elements as components ("II-VI group quantum dots”, "III-V group quantum dots”, " Or “Group IV quantum dots”). You may use individually or what mixed multiple types.
  • CdSe CdS, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN, InAs, InGaP, GaP, GaAs, Si, and Ge, but are not limited thereto.
  • a quantum dot having the above quantum dot as a core and a shell provided thereon.
  • the core is CdSe and the shell is ZnS
  • CdSe / ZnS when the core is CdSe and the shell is ZnS, it is expressed as CdSe / ZnS.
  • CdSe / ZnS, CdS / ZnS, InP / ZnS, InGaP / ZnS, Si / SiO 2 , Si / ZnS, Ge / GeO 2 , Ge / ZnS, and the like can be used, but are not limited thereto.
  • Quantum dots may be subjected to surface treatment with an organic polymer or the like as necessary.
  • organic polymer or the like as necessary. Examples thereof include CdSe / ZnS having a surface carboxy group (manufactured by Invitrogen), CdSe / ZnS having a surface amino group (manufactured by Invitrogen), and the like.
  • rare earth phosphors for example, neodymium oxide, neodymium chloride, neodymium nitrate, ytterbium oxide, ytterbium chloride, ytterbium nitrate, lanthanum oxide, lanthanum chloride, lanthanum nitrate, yttrium oxide, yttrium chloride, yttrium nitrate, pradiosem chloride, erbium chloride, Orthophosphoric acid, ammonium phosphate, ammonium dihydrogen phosphate and the like can be used.
  • fluorescent aggregate formed by accumulating a plurality of fluorescent substances a fluorescence having a core capable of immobilizing a large number of fluorescent substances and a shell made of a plurality of fluorescent substances immobilized on the core.
  • fluorescent aggregate particles composed of a core made of nanoparticles of an appropriate material such as silica nanoparticles and a shell made of a plurality of the above organic fluorescent dyes are preferably used.
  • tissue staining can be performed with a very high quantitativeness equivalent to that of the FISH method.
  • the fluorescent aggregate particles may be referred to as “phosphor aggregate particles”.
  • the term “nanoparticle” is used to mean a particle having a size on the order of nanometers (1 to several hundred nanometers).
  • the material constituting the core is not particularly limited as long as it can fix the shell on the surface and does not quench the fluorescence from the fluorescent material constituting the shell.
  • a suitable material silica and the like can be mentioned.
  • the fluorescent aggregate including a core made of silica nanoparticles and a shell made of a plurality of the organic fluorescent dyes is, for example, a functional group that can bind to a functional group of the organic fluorescent dye with respect to the organic fluorescent dye. It can be obtained as an organic fluorescent dye integrated / silica nanoparticle by reacting with a suitable silane coupling agent having the following formula and further reacting with a suitable tetraalkylsilane such as tetraethoxysilane.
  • an enzyme capable of generating a chromogenic substance from an appropriate substrate includes an enzyme that changes a substrate to generate a fluorescent species, such as horseradish peroxidase (HRP).
  • HRP horseradish peroxidase
  • examples include peroxidase, alkaline phosphatase (ALP), and glucosidase enzymes.
  • a substrate generally used as a fluorogenic substrate in a conventionally known assay method based on a fluorogenic substrate conversion method can be used as a substrate that is converted into a chromogenic substance by these enzymes.
  • substrates include oxidoreductase substrates such as horseradish peroxidase (HRP) substrates, phosphatase substrates such as alkaline phosphatase (ALP) substrates, and glycosidase substrates such as ⁇ -galactosidase substrates. Although it is mentioned, it is not limited to these.
  • substrates used in the enzymatic reaction by HRP include 3,3′-diaminobenzidine (DAB), 3-p-hydroxyphenylpropionic acid (HPPA), ECL plus (trademark), 4-chloro-1-naphthol, 4-chloronaphthalen-1-ol and the like.
  • a substrate used for an enzymatic reaction with alkaline phosphatase ALP
  • 5-bromo-4-chloro-3-indolyl phosphate / nitroblue tetrazolium salt BCIP / NBT
  • 4-methylumbelliferyl phosphate MUP
  • 6,8-difluoro-4-methylumbelliferyl phosphate DiFMUP
  • AttoPhos® 9H- (1,3-dichloro-9,9-dimethylacridin-2-one-7-yl
  • DDAOP phosphate
  • X-gal 5-bromo-4-chloro-3-indolyl- ⁇ -D-galactopyranoside
  • DDAOG 9H- (1,3-dichloro-9,9 -Dimethylacridin-2-one-7-yl) ⁇ -D-galactopyranoside
  • UMG 4-methylumbelliferyl- ⁇ -D-galactoside
  • a fluorescent labeling agent is preferably used because color development according to the amount of the complex produced by the antigen-antibody reaction can be obtained more reliably.
  • fluorescent labeling agents a fluorescent aggregate obtained by accumulating a plurality of fluorescent substances is particularly preferably used because high emission intensity can be easily obtained and excellent quantitativeness can be obtained.
  • the buffer solution according to the present invention is a solvent for stably maintaining an environment suitable for an antigen-antibody reaction.
  • phosphate buffer physiological saline PBS
  • phosphate buffer Tris buffer
  • MES buffer citrate-phosphate buffer
  • the immunohistochemical staining method visualizes the antigen-antibody reaction between a biological material present on the surface of a pathological slice tissue or cell and a substance recognizing the biological material, so that the biological material on the surface of the pathological slice tissue or cell is visualized. It is a method of judging whereabouts.
  • This immunohistochemical staining method is a technique generally called an immunohistochemical method.
  • visualization is performed through a change in color or brightness due to emission of fluorescence or the like, a change in color absorption, and the like, this visualization is sometimes referred to as “staining” in this specification.
  • the staining method of the present invention in this immunohistological staining method, the antigen targeted by the antibody drug is positioned as a target biological substance to be stained, and the antibody drug is used as a substance that recognizes the biological substance. It is characterized by using the antibody itself which is a constituent of
  • the staining method of the present invention is an immunohistochemical staining method using an antibody that is a component of the antibody drug as a substance that recognizes the antigen targeted by the antibody drug.
  • the staining method of the present invention is not limited to a pathological section tissue and can also be applied to cell staining.
  • the preparation method of a pathological section (hereinafter sometimes referred to as “section”) to which the staining method of the present invention can be applied is not particularly limited, and those prepared by a known method can be used.
  • a method for preparing such a section there is a paraffin method in which the collected tissue is embedded in paraffin and then sliced to obtain a section, or a method in which the collected tissue is frozen and sliced to obtain a section. Examples include frozen section method.
  • Paraffin removal can be performed, for example, in the following manner.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, xylene may be exchanged during the immersion.
  • the pathological section is immersed in a container containing ethanol to remove xylene.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, ethanol may be exchanged during the immersion.
  • the pathological section is immersed in a container containing water and ethanol is removed.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, water may be exchanged during the immersion.
  • Activation treatment step In the staining method of the present invention, as in the case of a conventionally known immunohistochemical staining method, in many cases, a purpose included in a pathological section or cell in advance so that good immunostaining is performed.
  • the biological material activation process is performed.
  • the activation process of the target biological substance can be performed by a conventionally known method.
  • the activation conditions are not particularly defined, but as the activation liquid, 0.01 M citrate buffer (pH 6.0), 1 mM EDTA solution (pH 8.0), 5% urea, 0.1 M Tris-HCl buffer, etc. should be used. Can do.
  • As the heating device an autoclave, a microwave, a pressure cooker, a water bath, or the like can be used.
  • the temperature is not particularly limited, but can be performed at room temperature. The temperature can be 50-130 ° C. and the time can be 5-30 minutes.
  • the section after activation treatment is immersed in a container containing water and PBS and washed.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, PBS may be replaced during the immersion.
  • the staining step detects an antigen targeted by the antibody drug present on the surface of a pathological section tissue or other cellular tissue (hereinafter sometimes referred to as “tissue”).
  • tissue a pathological section tissue or other cellular tissue
  • Antibody, antibody drug In the staining method of the present invention, when a tissue is stained, an antibody that is a component of the antibody drug is used as an antibody that recognizes an antigen targeted by the antibody drug present on the surface of the tissue. To do.
  • the term “antibody” is used to include any antibody fragment or derivative.
  • antibody drug refers to a pharmaceutical product containing an antibody as a constituent component. In addition to the antibody, if necessary, it includes other components such as an adjuvant such as a stabilizer and a pharmaceutically acceptable filler as a constituent component. It is a waste.
  • the term “antibody drug” may be used for an antibody that is a constituent component as long as the presence or absence of the other components is not a problem.
  • an antibody that is a component of an antibody drug may be referred to as an “antibody drug constituent antibody”.
  • antibody drug-constituting antibody recognizes an antigen targeted by the antibody drug and binds to the antigen through an antigen-antibody reaction to thereby exert a predetermined medicinal effect as a drug.
  • antibody drug constituent antibody an antibody having both a function of recognizing an antigen targeted by an antibody drug and a function of exerting a predetermined drug effect after binding to the antigen; and
  • An antibody drug has only a function of recognizing a target antigen, but exhibits a predetermined drug effect by transporting the drug active substance to a cell or tissue having the antigen as a complex with the drug active substance. And antibodies that contribute to.
  • the means for labeling the complex produced by the antigen-antibody reaction between the antigen targeted by the antibody drug and the antibody drug-constituting antibody is not particularly limited, but the form of the labeled antibody to which the labeling substance is bound. It is preferable to use an antibody pharmaceutical composition antibody.
  • an antibody drug used in the present invention, an antibody drug generally used for the treatment of autoimmune diseases such as rheumatoid arthritis, malignant tumors such as cancer, viral infections and the like can be used.
  • any one of a cancer growth regulator, a metastasis regulator, a growth regulator receptor, a metastasis regulator receptor, etc. is used as a target antigen, and the target antigen And those containing an antibody that binds to as an active ingredient.
  • an antibody that is, antibody drug component antibody contained as a component of such an antibody drug, (i ') an antibody that suppresses the growth of cancer cells by itself binding to cancer cells, or kills cancer cells; (ii ′) An antibody that functions as a means for transporting antitumor active substances such as anticancer agents, antiviral agents, antibiotics, and radiation-emitting substances to cancer cells.
  • Table 1 shows typical antibody drugs used in clinical practice.
  • antibody drugs used for the treatment of autoimmune diseases and infectious diseases are also listed in Table 1.
  • Herceptin is an antibody drug
  • trastuzumab is an antibody that is included as a component (that is, an antibody drug constituent antibody).
  • gemtuzumab is used in the form of Gemutuzumab-Ozogamicin formed by binding to an antitumor active substance, calicheamicin.
  • an antibody drug containing trastuzumab as a constituent component that is, Herceptin (registered trademark) is preferably used.
  • cancers to which the staining method of the present invention is applied include colorectal cancer, rectal cancer, kidney cancer, breast cancer, prostate cancer, uterine cancer, ovarian cancer, endometrial cancer, and esophagus. Cancer, blood cancer, liver cancer, pancreatic cancer, skin cancer, lung cancer, breast cancer and the like.
  • Antigen to be subjected to the staining method of the present invention is not particularly limited as long as it is a biological substance that functions as an antigen to be a target molecule of the above-described antibody drug.
  • the term “antigen” refers to a biological substance, in particular, a molecule or molecular fragment.
  • molecule or molecular fragment
  • nucleic acids single-stranded, DNA, RNA, polynucleotide, oligonucleotide, PNA (peptide nucleic acid) etc., or nucleoside, nucleotide and their modified molecules
  • protein polypeptide, oligopeptide etc.
  • amino acid (modified) Amino acids are also included
  • carbohydrates oligosaccharides, polysaccharides, sugar chains, etc.
  • lipids or modified molecules or complexes thereof, such as tumor markers, signaling substances, hormones, etc.
  • an antibody that is a constituent component of an antibody drug is used as the antibody, and therefore, among these “antigens”, those targeted by the antibody drug are to be detected.
  • an antigen targeted by an antibody drug may be referred to as an “antibody drug target antigen”.
  • cancer growth regulators cancer growth regulators, metastasis regulators, growth regulator receptors and metastasis regulator receptors are suitable target antigens. As mentioned.
  • metastasis regulators, growth regulator receptors and metastasis regulator receptors, cancer growth regulators and receptors include, for example, epidermal growth factor (EGF), The EGF receptor (EGFR), platelet-derived growth factor (PDGF), PDGF receptor (PDGFR), insulin-like growth factor (IGF), IGF receptor (IGFR) ), Fibroblast growth factor (FGF), the FGF receptor (FGFR), vascular endothelial growth factor (VEGF: Vascular Endotherial growth factor), the VEGF receptor (VEGFR), hepatocyte growth factor (HGF: Hepatocyte Growth Factor), the HGF receptor (HGFR), neurotrophic factor (NT: Neurotropin), transforming growth factor ⁇ (TGF ⁇ : Transforming Growth Factor- ⁇ ) Cell growth factors such as AMILY, HER2, and receptors thereof, and cyclin, cyclin-dependent kinase (CDK), cyclin A, cyclin B, cyclin D, cyclin E, CDK
  • CDK transforming
  • cancer metastasis regulators and receptors thereof include matrix metalloproteinase 1 (MMP1), matrix metalloproteinase 2 (MMP2), PAR1 (Protease Activated Receptor 1), CXCR4 (Chemokine [CX-C motif ] Receptor 4), CCR7 (Chemokine [C-C motif] receptor 7), etc.
  • MMP1 matrix metalloproteinase 1
  • MMP2 matrix metalloproteinase 2
  • PAR1 Protease Activated Receptor 1
  • CXCR4 Chemokine [CX-C motif ] Receptor 4
  • CCR7 Chemokine [C-C motif] receptor 7
  • trastuzumab targeting HER2 is widely used, and HER2 can be preferably exemplified. .
  • inflammatory cytokines such as TNF- ⁇ (Tumor Necrosis Factor ⁇ ) and IL-6 (Interleukin-6) receptors, virus-related molecules such as RSV F protein, and the like are also included in the present invention. Can be detected by the staining method.
  • the tissue staining means is not particularly limited as long as it can visualize the antigen-antibody reaction between the antibody drug target antigen and the antibody drug constituent antibody.
  • the antigen-antibody reaction is caused by the labeling. Since it can be expressed as a color change, the distribution of the antigen present in the tissue can be visualized according to the amount of the antibody bound to the antigen.
  • the labeled antibody contains the above-mentioned antibody drug-constituting antibody and the above-mentioned labeling substance, and the above-mentioned antibody drug-constituting antibody and the above-mentioned labeling substance comprise an amide bond, an ester bond, an imide bond, It has a structure bonded via an appropriate chemical bond such as a bond utilizing thiol addition to a maleimide group, or via a biotin-avidin bond or a biotin-streptavidin bond.
  • Such a labeled antibody can be obtained by binding the above-described labeling substance to the above-mentioned antibody pharmaceutical constituent antibody according to a conventional method.
  • Specific labeling methods include a method using an antibody (secondary antibody) having a specific affinity for the above-mentioned antibody pharmaceutical constituent antibody, a biotin-avidin method, a thiol group-maleimide group coupling reaction method , A method using an existing chemical linker, a cross-linking reaction method using a cross-linking agent (EDC, etc.), an ion binding method, etc. can be mentioned, and when the antibody is a humanized antibody or a human antibody, A preferred example is a thiol group-maleimide group coupling reaction method with an antibody or avidin.
  • the specific formation procedure is as follows, for example.
  • a first binding group is introduced into an antibody drug constituent antibody, and a second binding group that can bind to the first binding group is introduced into a labeling substance.
  • linkers having appropriate chain lengths may be interposed between the first binding group and the antibody drug constituent antibody and between the second binding group and the labeling substance.
  • the first and second linking groups may be chemical functional groups such as a carboxyl group, an amino group, an aldehyde group, a thiol group, and a maleimide group, or molecules such as biotin, avidin, and streptavidin. It may be.
  • the first binding group may be a site other than the site that recognizes the target antigen that constitutes the antibody drug constituent antibody.
  • a labeled antibody is obtained by reacting the antibody-drug-constituting antibody into which the first binding group has been introduced with a labeled substance into which the second binding group has been introduced.
  • This labeled antibody is prepared in advance in the absence of the tissue to be stained by reacting the antibody-drug-constituting antibody introduced with the first binding group with the labeled substance introduced with the second binding group.
  • the antibody incorporated in the tissue it may be formed by reacting a labeling substance introduced with a second binding group.
  • the staining using the labeled antibody can be performed by bringing the labeled antibody obtained by the labeling method shown in the section “ ⁇ Labeled antibody >>” into contact with the tissue to be stained.
  • an unlabeled antibody drug constituent antibody into which the first binding group has been introduced (hereinafter referred to as “an unlabeled antibody drug constituent antibody into which the first binding group has been introduced”) is brought into contact with the tissue to be stained. It can also be performed by forming an antigen-antibody complex and then binding the antigen-antibody complex with a labeling substance into which the second binding group has been introduced.
  • the tissue to be stained is preliminarily subjected to an activation treatment by the above-described activation treatment step so that good staining is performed, and nonspecific adsorption of a labeled antibody or the like is suppressed. Therefore, it is preferable to perform a blocking treatment in advance on the tissue surface to be stained using a known blocking agent such as a BSA-containing buffer solution.
  • Staining with this labeled antibody typically involves (i) using a known blocking agent, a step of performing a blocking treatment on the tissue surface to be stained; (ii) contacting the labeled antibody with the tissue surface that has undergone the step (i) to obtain a stained tissue; (iii) It can be carried out through a series of steps including the step of washing away the unreacted labeled antibody remaining on the stained tissue obtained in the step (ii).
  • an antibody drug-constituting antibody into which a first binding group has been introduced is obtained, for example, in the form of a biotinylated antibody drug-constituting antibody or the like by performing biotinylation or the like on the antibody drug.
  • phosphor-aggregated particles for example, streptavidin-modified phosphors are aggregated by binding streptavidin or the like via an appropriate linker in an appropriate buffer such as PBS (phosphate buffered saline).
  • PBS phosphate buffered saline
  • the phosphor integrated particles obtained from the antibody pharmaceutical constituent antibodies introduced with the first binding group and the phosphor integrated particles introduced with the second binding group Each labeled antibody dispersion in PBS is prepared, placed on a pathological section, and reacted with the target biological substance.
  • the “target biological substance” is a target antigen targeted by the antibody drug constituent antibody.
  • the PBS dispersion of the phosphor-aggregated particle-labeled antibody may contain a known blocking agent such as BSA-containing PBS and a surfactant such as Tween20.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the reaction time with the phosphor-aggregated particle-labeled antibody is preferably 30 minutes to 24 hours.
  • a known blocking agent such as BSA-containing PBS is preferably added dropwise before staining with the phosphor-aggregated particle-labeled antibody.
  • the stained section is immersed in a container containing PBS to remove the unreacted phosphor-aggregated particle-labeled antibody.
  • a PBS solution may contain a surfactant such as Tween20.
  • the temperature is not particularly limited, but can be performed at room temperature.
  • the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, PBS may be replaced during the immersion.
  • ⁇ Hematoxylin-eosin staining may be performed for tissue morphology observation.
  • the stained tissue can be subjected to pre-operations necessary for observation described later.
  • a pathological section is used as the tissue to be stained, a cover glass is placed on the section and sealed. At this time, you may use a commercially available mounting agent as needed.
  • the target biological substance existing on the stained tissue is measured by measuring the intensity of the fluorescent emission. Can evaluate the number.
  • the observation of the tissue stained in the form of a color pattern in the visible region can be performed by visual inspection without performing a secondary operation such as development.
  • the expression level of the target biological substance can be measured on the stained tissue such as a stained pathological section based on the number of bright spots or emission luminance.
  • the stained tissue such as a stained pathological section based on the number of bright spots or emission luminance.
  • a confocal microscope as a microscope, it is also possible to obtain three-dimensional information about the stained tissue, and from the three-dimensional image obtained through fluorescence, such as cancer cells contained in the stained tissue A distribution can also be obtained.
  • the excitation light source for fluorescence excitation a fluorescent material corresponding to the absorption maximum wavelength and fluorescence wavelength of the fluorescent substance used can be used as appropriate, and in order to separate excitation light from emitted fluorescence, fluorescence can be used as necessary.
  • An optical filter for detection can be used in combination.
  • the number of luminescent spots or emission luminance can be measured using image analysis software, for example, public analysis software ImageJ, or G-Count, a total luminescent spot automatic measurement software manufactured by Zeonstrom.
  • image analysis software for example, public analysis software ImageJ, or G-Count, a total luminescent spot automatic measurement software manufactured by Zeonstrom.
  • the staining method of the present invention described above can be applied to a method for determining the effectiveness of an antibody drug.
  • the present invention relates to the effectiveness of the antibody drug by measuring the amount of binding of the antibody that is a constituent of the antibody drug with respect to the amount of the antigen targeted by the antibody drug using the staining method described above.
  • a method for determining gender is also provided. That is, the determination method of the present invention intends to determine the effectiveness of an antibody drug by evaluating the amount of binding of the constituent antibody to the target antigen amount by the staining method described above. It is.
  • an antigen-antibody complex is produced by reacting and staining an antibody drug as a subject to a tissue in which a certain amount of effective target antigen is present. It is intended to judge the effectiveness of an antibody drug by visualizing and evaluating the amount of antigen-antibody complex produced based on the change in color development at that time.
  • the amount of effective target antigen in the tissue may vary depending on the condition of the acquired tissue, the activation process, and the like.
  • a genetic diagnosis method a conventionally known immunohistochemical method using an antibody drug as an antibody using a coloring reaction between an enzyme and a substrate, etc. It is preferable to make a comparison with the conventional determination method.
  • gene diagnosis methods include PCR method, Southern hybridization method, FISH method and the like.
  • immunohistochemical methods using a coloring reaction between an enzyme and a substrate include horseradish peroxidase (HRP) and the HRP.
  • Examples include methods using the substrate DAB, alkaline phosphatase (ALP) and the ALP substrate BCIP / NBT, ⁇ -galactosidase and the ⁇ -galactosidase substrate X-gal, and the like.
  • the FISH method and / or the immunohistochemistry (IHC-DAB) method using HRP and DAB can be preferably exemplified.
  • the pharmaceutical for which the effectiveness is judged includes an antibody as an active ingredient
  • the present invention is not limited to pharmaceuticals, and when a signal transduction pathway exists in a protein targeted by an antibody, a pharmaceutical that targets a factor (protein) in the signal transduction pathway is also included.
  • the antibody in the pharmaceutical comprising the above antibody as a component is HER2, for example, Ras, Raf, etc. as factors involved in cell proliferation downstream of HER2 signaling pathway, PI3K, AKT, etc. as factors involved in anti-apoptosis Can be mentioned.
  • an antibody in a pharmaceutical comprising an antibody as a component
  • an antibody that specifically recognizes a cancer growth regulator or a metastasis regulator is preferable, and examples of the type of antibody include a monoclonal antibody and a polyclonal antibody.
  • the class and subclass of the antibody are not particularly limited. Examples of the class include IgA, IgG, IgE, IgD, IgM, and the like. Examples of the subclass include IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, and the like. Can be mentioned.
  • the term “antibody” used herein is used to include any antibody fragment or derivative.
  • Fab fragment antigen binding protein
  • Fab ′ 2 fragment antigen binding protein
  • CDR single chain antibody
  • Such antibodies can be produced by known methods (see, for example, Harlow E. & Lane D., Antibody, Cold Spring Harbor Laboratory Press (1988)).
  • ⁇ Streptavidin-modified phosphor aggregated particles Synthesis of fluorescent particles (organic fluorescent dye) 6.6 mg of tetramethylrhodamine (TAMRA-SE manufactured by Invitrogen) (excitation wavelength: 550 nm, emission wavelength: 570 nm) and 3 ⁇ L of 3-aminopropyltrimethoxysilane (3-aminopropyltrimethoxysilane, manufactured by Shin-Etsu Silicone, KBM903) were mixed in DMF. An organoalkoxysilane compound was obtained.
  • TAMRA-SE tetramethylrhodamine
  • 0.6 ml of the obtained organoalkoxysilane compound was mixed with 48 ml of ethanol, 0.6 ml of TEOS (tetraethoxysilane), 2 ml of water, 2 ml of 28% ammonia water for 3 hours.
  • TEOS tetraethoxysilane
  • the mixed solution prepared in the above step was centrifuged at 10,000 G for 20 minutes, and the supernatant was removed. Ethanol was added to disperse the sediment and centrifuged again. In the same procedure, washing with ethanol and pure water was performed twice. As a result, 10 mg of tetramethylrhodamine-aggregated / silica nanoparticles were obtained as phosphor-aggregated particles.
  • InP / ZnS soot core / shell particles were synthesized using this InP core particle dispersion.
  • this mixture was heated from 80 ° C. to 230 ° C.
  • InP / ZnSIncore / shell particles were obtained as a precipitate.
  • the thus obtained InP / ZnS core / shell semiconductor nanoparticles were particles having a maximum emission wavelength at 630 nm.
  • a water-soluble semiconductor nanoparticle solution can be obtained by adding 0.1 mg of dodecylamine and 1 mL of ultrapure water to 0.1 mg of this InP / ZnS core / shell particle and stirring strongly for 1 h.
  • the water-soluble semiconductor nanoparticle solution was subjected to hydrolysis by adding 0.1 mg of TEOS, 0.01 mL of ethanol, and 0.03 mL of concentrated ammonia water to obtain an InP, CdSe, CdTe semiconductor nanoparticle aggregate.
  • Phosphor-aggregated particles are dissolved in PBS (phosphate buffered saline) containing 2 mM of EDTA (ethylenediaminetetraacetic acid) and adjusted to 3 nM, and SM (PEG) 12 ( Succinimidyl-[(N-maleidopropionamid) -dodecaethyleneglycol] ster) manufactured by Thermo Scientific was mixed and reacted for 1 hour. The mixture was centrifuged at 10,000 G for 20 minutes, the supernatant was removed, PBS containing 2 mM of EDTA was added, the precipitate was dispersed, and centrifuged again. The silica nanoparticle for antibody binding was obtained by performing washing
  • streptavidin is reduced with 1M dithiothreitol (DTT) or thiol group addition treatment such as SATA, and a reduced antibody solution capable of binding to silica particles is removed by removing excess reaction reagent with a gel filtration column. Obtained.
  • DTT dithiothreitol
  • SATA thiol group addition treatment
  • the antibody-binding silica nanoparticles obtained above and the reduced antibody were mixed in PBS containing 2 mM EDTA and allowed to react for 1 hour. 10 mM mercaptoethanol was added to stop the reaction. The resulting solution was centrifuged at 10,000 G for 20 minutes, the supernatant was removed, PBS containing 2 mM of EDTA was added, the precipitate was dispersed, and centrifuged again. By performing washing by the same procedure three times, streptavidin-bonded / phosphor-integrated silica nanoparticles were obtained.
  • Example 3 the streptavidin-bonded / phosphor-integrated silica nanoparticles were used as streptavidin-modified phosphor-integrated particles.
  • Example 2 tissue staining (HRP)
  • Human breast tissue was immunostained using biotinylated trastuzumab and streptavidin-modified HRP prepared in Example 1.
  • the staining method of the present invention using this biotinylated trastuzumab and streptavidin-modified HRP may be hereinafter referred to as “trastuzumab-HRP”.
  • tissue array slide (CB-A712) manufactured by Cosmo Bio, whose FISH score was calculated in advance using a Pathvision HER-2 DNA probe kit (Abbott), was used.
  • the tissue array slide was deparaffinized, washed with water, and autoclaved in 10 mM citrate buffer (pH 6.0) for 15 minutes to activate the antigen.
  • the tissue array slide after the antigen activation treatment was washed with PBS buffer, and then subjected to blocking treatment with a 1% BSA-containing PBS buffer in a wet box for 1 hour.
  • trastuzumab and a tissue modified with HRP were obtained.
  • This Herceptin-HRP modified tissue was stained by a conventional method using a DAB (diaminobenzidine tetrahydrochloride) solution as a substrate solution.
  • tissue staining without using antibody drugs examples include Histofine HER2 kit (Nichirei: “N company staining kit”), Dako Hercept Test II (Dako: “D company staining kit”), Ventana I-VIEW pathway Staining was performed using HER2 (4B5) (Roche: “R company staining kit”).
  • the score of the stained tissue was calculated based on the determination standard of HER2 inspection guide-revised third edition according to the staining concentration.
  • Table 2 shows a comparison of staining scores and FISH scores using kits from each company and trastuzumab-HRP.
  • a staining score of “trastuzumab-HRP” corresponds to a staining score for a tissue stained by the staining method of the present invention.
  • Table 3 shows the correlation between the staining score using each company's kit and trastuzumab-HRP and the FISH score. It can be seen that the staining score using trastuzumab-HRP shows a high correlation with the FISH score as compared with the staining score of each company's kit not using the antibody drug.
  • Example 3 Tissue staining (phosphor-aggregated particles)]
  • human breast tissue was immunostained using streptavidin-modified phosphor-aggregated particles as a label. That is, except that the tissue section that had been reacted with biotinylated trastuzumab was reacted with each of the streptavidin-modified phosphor-aggregated particles obtained in Example 1 instead of streptavidin-modified HRP.
  • the immunostaining was performed by the same procedure as in No.
  • trastuzumab-phosphor-aggregated particles Stained tissue sections were imaged using an Olympus DSU confocal microscope, the cancer cell area was identified, binary processing using image J was performed, and bright spot measurement was performed after noise removal processing. The number of bright spots was measured.
  • Table 4 shows a comparison of the FISH score with the staining score using trastuzumab-HRP, the number of bright spots per 10 cells in the tissue stained with each trastuzumab-phosphor aggregated particle, and the FISH score.
  • Table 5 shows the correlation comparison with the FISH score for staining scores using trastuzumab-HRP and each trastuzumab-phosphor aggregated particle. It can be seen that the data on the number of bright spots measured using each trastuzumab-phosphor aggregated particle shows a higher correlation with the FISH score than the staining score using trastuzumab-HRP.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Cette invention concerne un procédé de coloration immunohistologique qui donne une coloration de précision élevée à l'aide d'une préparation d'anticorps contenant, à titre de composant, un anticorps tel que le trastuzumab à titre de substance qui reconnaît une substance biologique cible, et concerne également un procédé permettant de déterminer l'efficacité d'une préparation d'anticorps à une précision élevée à l'aide dudit procédé de coloration immunohistologique. Le procédé de coloration immunohistologique selon l'invention fait appel à un anticorps qui est un composant constitutif d'une préparation d'anticorps à titre de substance qui reconnaît un antigène qui doit être ciblé par la préparation d'anticorps. Un procédé de détermination de l'efficacité de la préparation d'anticorps par mesure de la quantité de liaison de l'anticorps par rapport à la quantité d'antigène à l'aide dudit procédé de coloration immunohistologique est également décrit.
PCT/JP2012/057191 2011-03-25 2012-03-21 Procédé de coloration immunohistologique pour déterminer l'efficacité d'une préparation d'anticorps l'utilisant WO2012133047A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013507430A JP5900489B2 (ja) 2011-03-25 2012-03-21 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011067448 2011-03-25
JP2011-067448 2011-03-25

Publications (1)

Publication Number Publication Date
WO2012133047A1 true WO2012133047A1 (fr) 2012-10-04

Family

ID=46930779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/057191 WO2012133047A1 (fr) 2011-03-25 2012-03-21 Procédé de coloration immunohistologique pour déterminer l'efficacité d'une préparation d'anticorps l'utilisant

Country Status (2)

Country Link
JP (1) JP5900489B2 (fr)
WO (1) WO2012133047A1 (fr)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235081A (ja) * 2013-06-03 2014-12-15 コニカミノルタ株式会社 免疫染色方法、蛍光免疫染色用前処理液および免疫染色用キット
WO2015133523A1 (fr) * 2014-03-06 2015-09-11 コニカミノルタ株式会社 Agent de marquage de nanoparticules de phosphore intégrées, et procédé d'immunocoloration fluorescente l'utilisant
WO2015159776A1 (fr) * 2014-04-16 2015-10-22 コニカミノルタ株式会社 Nanoparticules d'agregat de phosphore, reactif colorant utilisant celles-ci, trousse et procede d'immunocoloration fluorescente
JP2015230293A (ja) * 2014-06-06 2015-12-21 古河電気工業株式会社 生体分子検出用試験キット、及びこれを用いた生体分子の検出方法、並びにこれらに用いられる生体分子検出用試験片及び生体分子検出用標識試薬
WO2016013541A1 (fr) * 2014-07-23 2016-01-28 コニカミノルタ株式会社 Réactif de marquage contenant un médicament à cible moléculaire
JP2016024105A (ja) * 2014-07-23 2016-02-08 コニカミノルタ株式会社 ソラフェニブを含有する標識剤
WO2016129444A1 (fr) * 2015-02-12 2016-08-18 コニカミノルタ株式会社 Nanoparticules de phosphore intégrées conjuguées à des anticorps, procédé permettant de fabriquer des nanoparticules de phosphore intégrées conjuguées à des anticorps et kit d'immunocoloration
WO2016175275A1 (fr) * 2015-04-30 2016-11-03 国立大学法人京都大学 Procédé pour prévoir l'effet thérapeutique d'un inhibiteur de pd-1/pd-l1 en utilisant une anomalie dans pd-l1(cd274) comme indice
JP2017026375A (ja) * 2015-07-17 2017-02-02 コニカミノルタ株式会社 蛍光体集積ナノ粒子を用いたｆｉｓｈまたは免疫染色スライドの封入方法
JPWO2015141856A1 (ja) * 2014-03-20 2017-04-13 コニカミノルタ株式会社 プローブ試薬および該プローブ試薬を用いたｆｉｓｈ
WO2018025869A1 (fr) * 2016-08-01 2018-02-08 株式会社ファーマフーズ Biomarqueur pour prédiction de l'effet thérapeutique d'un inhibiteur de fstl1 chez un patient cancéreux
JPWO2017056844A1 (ja) * 2015-09-28 2018-07-12 コニカミノルタ株式会社 前立腺癌の病理組織診断結果（グリーソンスコア）の推定方法
WO2018159212A1 (fr) 2017-02-28 2018-09-07 コニカミノルタ株式会社 Procédé de détection d'un composant constitutif d'un conjugué anticorps-médicament
WO2018185943A1 (fr) 2017-04-07 2018-10-11 コニカミノルタ株式会社 Particules fluorescentes pour prémélange, colorant fluorescent en contenant et procédé de marquage fluorescent les utilisant
WO2018185942A1 (fr) 2017-04-07 2018-10-11 コニカミノルタ株式会社 Procédé de fabrication d'un produit purifié de particule intégrée au phosphore modifié par une protéine, procédé de fabrication de liquide de coloration fluorescent, produit purifié de particule intégrée au phosphore modifié par une protéine, et filtre de purification d'un liquide de coloration fluorescent et d'une particule intégrée au phosphore modifiée par une protéine
WO2019131727A1 (fr) 2017-12-27 2019-07-04 コニカミノルタ株式会社 Procédé pour évaluer un médicament
CN110333353A (zh) * 2019-07-18 2019-10-15 武汉原谷生物科技有限责任公司 一种基于量子点标记的多重免疫组化分析试剂盒及分析方法
JPWO2018164262A1 (ja) * 2017-03-10 2020-01-09 コニカミノルタ株式会社 治療有効性の予測方法
WO2020148985A1 (fr) 2019-01-18 2020-07-23 コニカミノルタ株式会社 Nanoparticules intégrées au phosphore pour la détection d'une substance cible
WO2020255906A1 (fr) 2019-06-20 2020-12-24 コニカミノルタ株式会社 Corps lié pour agents de marquage fluorescents
JP2021519284A (ja) * 2018-03-27 2021-08-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506943A (ja) * 2002-02-11 2006-03-02 ジェネンテック・インコーポレーテッド 抗原結合速度の大きい抗体変異体
WO2008041594A1 (fr) * 2006-09-26 2008-04-10 Olympus Corporation procÉdÉ d'analyse de la sensibilitÉ À un mÉdicament À base d'anticorps
JP2009509171A (ja) * 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
WO2012029269A1 (fr) * 2010-09-02 2012-03-08 国立大学法人東北大学 Méthode de détermination de l'apparition d'un cancer ou du risque d'apparition d'un cancer
WO2012035705A1 (fr) * 2010-09-17 2012-03-22 国立大学法人東北大学 Méthode de détermination de l'efficacité d'un médicament contenant un anticorps comme composant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3468750B2 (ja) * 1998-01-22 2003-11-17 ルミネックス コーポレイション 多数の蛍光シグナルを有する微小粒子
JP4009722B2 (ja) * 2003-05-28 2007-11-21 独立行政法人産業技術総合研究所 ナノ粒子で装飾された無機成形体及びその製造方法
US20100252778A1 (en) * 2007-08-28 2010-10-07 National Institute Of Advanced Industrial Science And Technology Novel nanoparticle phosphor
KR100972618B1 (ko) * 2007-10-19 2010-07-27 국립암센터 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법
US20100224831A1 (en) * 2009-03-06 2010-09-09 Kyoungja Woo Nanoparticle-doped porous bead and fabrication method thereof
JP5416039B2 (ja) * 2010-06-03 2014-02-12 古河電気工業株式会社 標識試薬シリカナノ粒子
EP3225990B1 (fr) * 2010-08-30 2020-07-08 Konica Minolta, Inc. Particule pour colorer un tissue

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506943A (ja) * 2002-02-11 2006-03-02 ジェネンテック・インコーポレーテッド 抗原結合速度の大きい抗体変異体
JP2009509171A (ja) * 2005-09-21 2009-03-05 シーシーシー ダイアグノスティックス， エルエルシー 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
WO2008041594A1 (fr) * 2006-09-26 2008-04-10 Olympus Corporation procÉdÉ d'analyse de la sensibilitÉ À un mÉdicament À base d'anticorps
WO2012029269A1 (fr) * 2010-09-02 2012-03-08 国立大学法人東北大学 Méthode de détermination de l'apparition d'un cancer ou du risque d'apparition d'un cancer
WO2012035705A1 (fr) * 2010-09-17 2012-03-22 国立大学法人東北大学 Méthode de détermination de l'efficacité d'un médicament contenant un anticorps comme composant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEE, DONG KWAN ET AL.: "Preparation of near- infrared quantum dots-herceptin conjugates for cancer imaging", MACROMOLECULAR RESEARCH, vol. 18, no. 7, July 2010 (2010-07-01), pages 641 - 647, XP008163077, DOI: doi:10.1007/s13233-010-0707-6 *
TAKEO ITO: "Soshiki Saibo Kagaku 2006 - Idenshi Bunshi kara Saibo Soshiki eno Kaiki -I. Men'eki Soshiki Saibo Kagaku - Kiso kara Oyo - Keiko Kotai no Aratana Tenkai - Nano Crystal Men'eki Keiko Kotaiho", SOSHIKI SAIBO KAGAKU, vol. 2006, 2006, pages 25 - 34, XP008168872 *
TOMONOBU WATANABE: "Kyoshoten Laser Kenbi System o Mochiita in vivo, in vitro ni Okeru Saibonai Shingo Dentatsu Keisoku Shuho no Kakuritsu ni Kansuru Kenkyu", SEITAI CHO BISAI 1 BUNSHI KASHIKA GIJUTSU NI YORU NANO DDS TO GAN HYOTEKI CHIRYO NI KANSURU KENKYU, HEISEI 18 NENDO SOKATSU BUNTAN KENKYU NENDO SHURYO HOKOKUSHO, 2007, pages 15 - 17, XP001539090 *
YUKIKO OTSUKA ET AL.: "Formalin Kotei Paraffin Homai Hyohon kara Dokomade Idenshi Kensaku wa Kanoka ? Nyugan ni Okeru HER-2 Idenshi Ijo no FISH Kaiseki - Yuyosei to Chuiten, Men'eki Soshiki Kagaku tono Hikaku", CLINICAL TESTING, vol. 50, no. 7, 2006, pages 753 - 760 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235081A (ja) * 2013-06-03 2014-12-15 コニカミノルタ株式会社 免疫染色方法、蛍光免疫染色用前処理液および免疫染色用キット
JPWO2015133523A1 (ja) * 2014-03-06 2017-04-06 コニカミノルタ株式会社 蛍光体集積ナノ粒子標識剤、およびこれを用いた蛍光免疫染色法
US10509039B2 (en) 2014-03-06 2019-12-17 Konica Minolta, Inc. Integrated phosphor nanoparticle marking agent, and fluorescent immunostaining employing same
WO2015133523A1 (fr) * 2014-03-06 2015-09-11 コニカミノルタ株式会社 Agent de marquage de nanoparticules de phosphore intégrées, et procédé d'immunocoloration fluorescente l'utilisant
US10323271B2 (en) 2014-03-20 2019-06-18 Konica Minolta, Inc. Probe reagent and fish using probe reagent
EP3121291A4 (fr) * 2014-03-20 2017-08-30 Konica Minolta, Inc. Réactif sonde, et réactif sonde utilisant la technique fish
JPWO2015141856A1 (ja) * 2014-03-20 2017-04-13 コニカミノルタ株式会社 プローブ試薬および該プローブ試薬を用いたｆｉｓｈ
WO2015159776A1 (fr) * 2014-04-16 2015-10-22 コニカミノルタ株式会社 Nanoparticules d'agregat de phosphore, reactif colorant utilisant celles-ci, trousse et procede d'immunocoloration fluorescente
JPWO2015159776A1 (ja) * 2014-04-16 2017-04-13 コニカミノルタ株式会社 蛍光体集積ナノ粒子、これを用いた染色試薬、キットおよび蛍光免疫染色法
JP2015230293A (ja) * 2014-06-06 2015-12-21 古河電気工業株式会社 生体分子検出用試験キット、及びこれを用いた生体分子の検出方法、並びにこれらに用いられる生体分子検出用試験片及び生体分子検出用標識試薬
WO2016013541A1 (fr) * 2014-07-23 2016-01-28 コニカミノルタ株式会社 Réactif de marquage contenant un médicament à cible moléculaire
JP2016024105A (ja) * 2014-07-23 2016-02-08 コニカミノルタ株式会社 ソラフェニブを含有する標識剤
JPWO2016013541A1 (ja) * 2014-07-23 2017-05-25 コニカミノルタ株式会社 分子標的薬を含有する標識剤
WO2016129444A1 (fr) * 2015-02-12 2016-08-18 コニカミノルタ株式会社 Nanoparticules de phosphore intégrées conjuguées à des anticorps, procédé permettant de fabriquer des nanoparticules de phosphore intégrées conjuguées à des anticorps et kit d'immunocoloration
JPWO2016129444A1 (ja) * 2015-02-12 2017-11-24 コニカミノルタ株式会社 抗体結合蛍光体集積ナノ粒子、抗体結合蛍光体集積ナノ粒子の製造方法および免疫染色キット
WO2016175275A1 (fr) * 2015-04-30 2016-11-03 国立大学法人京都大学 Procédé pour prévoir l'effet thérapeutique d'un inhibiteur de pd-1/pd-l1 en utilisant une anomalie dans pd-l1(cd274) comme indice
JP2017026375A (ja) * 2015-07-17 2017-02-02 コニカミノルタ株式会社 蛍光体集積ナノ粒子を用いたｆｉｓｈまたは免疫染色スライドの封入方法
JPWO2017056844A1 (ja) * 2015-09-28 2018-07-12 コニカミノルタ株式会社 前立腺癌の病理組織診断結果（グリーソンスコア）の推定方法
WO2018025869A1 (fr) * 2016-08-01 2018-02-08 株式会社ファーマフーズ Biomarqueur pour prédiction de l'effet thérapeutique d'un inhibiteur de fstl1 chez un patient cancéreux
JP7012363B2 (ja) 2016-08-01 2022-01-28 株式会社ファーマフーズ がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
JPWO2018025869A1 (ja) * 2016-08-01 2019-07-11 株式会社ファーマフーズ がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
WO2018159212A1 (fr) 2017-02-28 2018-09-07 コニカミノルタ株式会社 Procédé de détection d'un composant constitutif d'un conjugué anticorps-médicament
US11662348B2 (en) 2017-02-28 2023-05-30 Konica Minolta, Inc. Method for detecting constituent component of antibody-drug conjugate
JPWO2018159212A1 (ja) * 2017-02-28 2019-06-27 コニカミノルタ株式会社 抗体−薬物複合体の構成成分の検出方法
EP3591399A4 (fr) * 2017-02-28 2020-01-22 Konica Minolta, Inc. Procédé de détection d'un composant constitutif d'un conjugué anticorps-médicament
CN110402391A (zh) * 2017-02-28 2019-11-01 柯尼卡美能达株式会社 抗体-药物复合体的构成成分的检测方法
JPWO2018164262A1 (ja) * 2017-03-10 2020-01-09 コニカミノルタ株式会社 治療有効性の予測方法
JP7140103B2 (ja) 2017-03-10 2022-09-21 コニカミノルタ株式会社 治療有効性の予測方法
WO2018185942A1 (fr) 2017-04-07 2018-10-11 コニカミノルタ株式会社 Procédé de fabrication d'un produit purifié de particule intégrée au phosphore modifié par une protéine, procédé de fabrication de liquide de coloration fluorescent, produit purifié de particule intégrée au phosphore modifié par une protéine, et filtre de purification d'un liquide de coloration fluorescent et d'une particule intégrée au phosphore modifiée par une protéine
WO2018185943A1 (fr) 2017-04-07 2018-10-11 コニカミノルタ株式会社 Particules fluorescentes pour prémélange, colorant fluorescent en contenant et procédé de marquage fluorescent les utilisant
WO2019131727A1 (fr) 2017-12-27 2019-07-04 コニカミノルタ株式会社 Procédé pour évaluer un médicament
JPWO2019131727A1 (ja) * 2017-12-27 2021-02-12 コニカミノルタ株式会社 医薬の評価方法
JP2021519284A (ja) * 2018-03-27 2021-08-10 ラボラトリー コーポレイション オブ アメリカ ホールディングス 治療薬による処置から利益を受けうる被験体を特定するためのサンドウィッチｅｌｉｓａ
WO2020148985A1 (fr) 2019-01-18 2020-07-23 コニカミノルタ株式会社 Nanoparticules intégrées au phosphore pour la détection d'une substance cible
WO2020255906A1 (fr) 2019-06-20 2020-12-24 コニカミノルタ株式会社 Corps lié pour agents de marquage fluorescents
CN110333353A (zh) * 2019-07-18 2019-10-15 武汉原谷生物科技有限责任公司 一种基于量子点标记的多重免疫组化分析试剂盒及分析方法

Also Published As

Publication number Publication date
JP5900489B2 (ja) 2016-04-06
JPWO2012133047A1 (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
JP5900489B2 (ja) 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
US11435348B2 (en) Tissue staining method
US10082508B2 (en) Automated analysis of circulating tumor cells
JP5906623B2 (ja) 生体物質発現レベル評価システム
US9632081B2 (en) Detection method for biological substance
US9970847B2 (en) Method for staining tissue
US11726090B2 (en) Means and methods for diagnosing pancreatic cancer
JP6259828B2 (ja) 未分化リンパ腫キナーゼ（ａｌｋ）をマーカーとして使用する治療応答性非小細胞肺癌の同定法
CN104364649B (zh) 用于鉴定具有基因毒性的化合物的蛋白表达分析
JP6424826B2 (ja) 組織切片における生体物質の定量法
WO2019131727A1 (fr) Procédé pour évaluer un médicament
JP5863057B2 (ja) 組織評価方法
CN111491667A (zh) 肽核酸缀合物
JP6922444B2 (ja) 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法
EP4067502A1 (fr) Procédé de visualisation et procédé d'acquisition d'informations
JP7162398B2 (ja) 早期膵がん検出アッセイ
KR20240022906A (ko) 암 진단용 다중 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12763026

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013507430

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12763026

Country of ref document: EP

Kind code of ref document: A1